<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>DT(388)IL3 fusion protein containing the catalytic and translocation domains of <z:e sem="disease" ids="C0012546" disease_type="Disease or Syndrome" abbrv="">diphtheria</z:e> toxin fused to human interleukin 3 was administered in an inter-patient dose escalation trial by 15 min i.v. infusions every other day for up to 6 doses to patients with chemo-refractory <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>The maximal tolerated dose was &gt;12.5 microg/kg/dose </plain></SENT>
<SENT sid="2" pm="."><plain>Transient grade 3 transaminasemia and grade 2 <z:hpo ids='HP_0001945'>fevers</z:hpo>, chills, <z:hpo ids='HP_0003073'>hypoalbuminemia</z:hpo>, and <z:hpo ids='HP_0002615'>hypotension</z:hpo> occurred </plain></SENT>
<SENT sid="3" pm="."><plain>Peak DT(388)IL3 levels correlated with dose and day of administration but not antibody titer </plain></SENT>
<SENT sid="4" pm="."><plain>Anti-DT(388)IL3 antibodies developed in most patients between day 15 and 30 </plain></SENT>
<SENT sid="5" pm="."><plain>Of 40 evaluable <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients, 1 had a CR (8 months) and 1 had PR (3 months) </plain></SENT>
<SENT sid="6" pm="."><plain>Of 5 MDS patients, 1 had a PR (4 months) </plain></SENT>
<SENT sid="7" pm="."><plain>Because of the prolonged infusion schedule, many patients failed to receive six doses </plain></SENT>
<SENT sid="8" pm="."><plain>DT(388)IL3 produces remissions in patients with relapsed/refractory <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with minimal toxicities, and alternate schedules of administration are needed to enhance the response rate </plain></SENT>
</text></document>